The North America Continuous Bioprocessing Market was valued at USD 1,210 Million in 2025 and is expected to reach USD 4,790 Million by 2035, growing at a CAGR of 13.2% from 2024 to 2035. This robust growth is fueled by advancements in bioprocessing technologies, increasing investments in biopharmaceutical R&D, and greater adoption of automation for enhanced process efficiency.
The economic impact of tariffs on "North America Continuous Bioprocessing Market".
Market Growth Drivers
Rising Investment in Biopharmaceutical R&D: Increased funding in biopharmaceutical research and development—from both public and private sectors—has accelerated the demand for continuous bioprocessing technologies. For instance, Thermo Fisher Scientific has expanded its bioproduction capabilities in North America, supporting advanced therapeutic development and commercialization. Biopharmaceutical companies are shifting from traditional batch processing to continuous processing, citing improved yields and cost-effectiveness as main drivers.
Technological Advancements and Automation: The industry is witnessing rapid advancements in automation technology integrated into continuous bioprocessing systems. Companies like Sartorius AG have been deploying real-time control and monitoring solutions which enhance productivity, reduce human error, and streamline operations. The result is reduced downtime and waste, making these solutions attractive for companies focusing on process optimization and scalability.
Market Trends
Adoption of Single-Use Technologies: Single-use systems are increasingly being adopted in continuous bioprocessing due to their flexibility and reduced risk of cross-contamination. In April 2024, Cytiva launched a new line of modular, single-use bioprocessing systems in North America that enable quicker changeovers and lower cleaning requirements. This trend significantly decreases operational downtime while supporting multiproduct manufacturing environments.
Expansion into Biosimilars and Personalized Medicines: The push towards biosimilar production and personalized medicine is a notable trend. Companies such as Pfizer and Amgen are actively leveraging continuous bioprocessing to quickly scale up manufacturing and reduce time-to-market for tailored therapeutics. The flexibility and efficiency offered by continuous processes facilitate small-batch, high-value biologics production, which is crucial for personalized therapy approaches.
Market Opportunities
Expansion in Contract Development and Manufacturing Organizations (CDMOs): With the growing demand for flexible and rapid bioproduction, North American CDMOs like Lonza are expanding their continuous bioprocessing services. This offers an excellent opportunity to capture outsourcing demand from small and mid-sized biotechs.
Integration of Artificial Intelligence and Data Analytics: The integration of AI and advanced data analytics into continuous bioprocessing platforms offers opportunities for predictive maintenance, enhanced process optimization, and real-time quality monitoring. Companies such as GE Healthcare are investing in digital bioprocessing innovations to stay ahead in the market.
North America Continuous Bioprocessing Market Revenue (USD Million), 2020-2035
The revenue chart displays a strong upward trajectory in the North America Continuous Bioprocessing Market between 2020 and 2035. Starting at USD 460 Million in 2020, the market demonstrates steady growth, crossing USD 1,210 Million by 2025, and reaching USD 4,790 Million by 2035. This growth trend illustrates the market’s dynamic expansion, driven by continuous technology enhancement and increasing adoption across pharmaceutical and biotechnology sectors. Key revenue milestones are marked during 2025-2030 with the acceleration of investments, ultimately leading to sustained double-digit growth rates over the forecast period. The chart underscores the increasing significance of continuous bioprocessing in regional biomedical manufacturing.
North America Continuous Bioprocessing Market by Regions Share (%), 2025
The pie chart for 2025 shows the regional market share distribution in North America. The United States commands the largest portion at 75%, reflecting its leading role in biopharmaceutical innovation and manufacturing capabilities. Canada follows with 18%, buoyed by increased biotech R&D investments and supportive governmental policies. Mexico holds 5%, with the remaining 2% distributed among other regions such as Puerto Rico and Central America. The dominance of the U.S. is attributed to the concentration of key market players, advanced healthcare infrastructure, and considerable research funding, emphasizing its pivotal role in the region's continuous bioprocessing landscape.
Recent Developments
In April 2024, Thermo Fisher Scientific announced the opening of a new continuous bioprocessing innovation center in Boston, USA, focused on developing end-to-end single-use solutions and automation for biologics manufacturing. The center will serve as a collaboration hub for academic partners, biotechs, and contract manufacturers, aiming to shorten development cycles and accelerate market entry for novel therapies.
In March 2024, Sartorius launched its new Biostat STR Generation 4 platform in North America, featuring real-time analytics and fully integrated automation modules for continuous bioprocessing. This enables customers to achieve higher throughput and process robustness, supporting both large-volume and multiproduct facilities, and addressing the region’s growing demand for scalable manufacturing solutions.
In January 2024, Cytiva expanded its manufacturing facility in Toronto, Canada, to enhance capacity for modular, single-use continuous bioprocessing systems. This expansion is in response to increased biotherapeutics demand from both local and U.S.-based clients, signifying ongoing investments in bioprocessing infrastructure and reinforcing Cytiva’s commitment to regional supply chain resilience.
Press Releases